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Abstract
Background. The treatment of patients with relapsed or refractory Hodgkin lymphoma (HL) and non-Hodgkin 
lymphoma (NHL) remains challenging. Gemcitabine is a cytidine analog with a wide spectrum of antitumor activ-
ity. Gemcitabine treatment is widely used to treat patients with certain solid tumors and relapsed/refractory hema-
tological malignancies. There are several reports indicating that this compound is active in lymphoid malignancies. 
In patients with relapsed or refractory HL and NHL, gemcitabine has demonstrated efficacy as a single agent and 
in combination with other cytostatics.
Objectives. The aim of the study was to analyze the efficacy and toxicity of gemcitabine-based chemotherapy in 
patients with relapsed or refractory lymphomas.
Material and Methods. The study evaluated 68 heavily pretreated patients with relapsed/refractory HL and NHL. 
The median age of the patients was 36  years. All the patients received gemcitabine-based chemotherapy (gem-
citabine monotherapy or gemcitabine in combination with other cytostatics).
Results. The overall response rate was 46%. Complete response was achieved by 21% of the patients and partial 
response by 25%. Out of those who responded to gemcitabine treatment, 26 patients proceeded to autologous stem 
cell transplant. Toxicities connected with gemcitabine therapy occurred in 44% of the patients and included grade 
3/4 neutropenia, thrombocytopenia and anemia.
Conclusions. The results suggest that gemcitabine-based salvage chemotherapy is effective and well tolerated in 
patients with relapsed/refractory HL and NHL (Adv Clin Exp Med 2015, 24, 5, 783–789).
Key words: Hodgkin lymphoma, gemcitabine, non-Hodgkin lymphoma, refractory disease, autologous stem cell 
transplant.
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The treatment of patients with relapsed or re-
fractory Hodgkin lymphoma (HL) and non-Hodg-
kin lymphoma (NHL) remains challenging. In gen-
eral, the standard care is high-dose chemotherapy 
followed by autologous stem cell transplant (ASCT) 
for patients who are sensitive to salvage chemother-
apy. There are no standard options of treatment for 
patients who show no response to second-line regi-
mens, nor for patients who are not eligible for trans-
plants [1, 2]. For those patients it is therefore very 
important to establish the satisfactory salvage ther-
apy with optimal response and a low toxicity rate.
Gemcitabine is a  cytidine analog with a  wide 
spectrum of antitumor activity. Gemcitabine needs 
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to be phosphorylated to gemcitabine monophos-
phate (dFdCMP) by deoxycytidine kinase (dCK), 
which is then converted to gemcitabine di- and tri-
phosphate (dFdCDP and dFdCTP – the active drug 
metabolites) [3, 4]. Gemcitabine is widely used in 
the treatment of patients with metastatic pancreat-
ic cancer, non-small cell lung cancer, bladder can-
cer, breast cancer and ovarian cancer [5–8].
In patients with relapsed or refractory HL and 
NHL, gemcitabine has demonstrated efficacy as 
a  single agent and in combination with other cy-
tostatics such as cisplatin, vinorelbine and liposo-
mal doxorubicin [9, 10]. Bartlett et al. reported an 
overall response rate (ORR) of 70% in patients with 
relapsed HL treated with a  combination of gem-
citabine, vinorelbine and liposomal doxorubicin 
(GVD regimen) [11]. In patients with resistant non- 
-Hodgkin lymphoma, the ORR after gemcitabine 
in combination with cisplatin and dexamethasone 
was 32%  [12]. Gemcitabine is active in lymphoid 
malignancies but the optimal schedule and combi-
nation remain to be established.
The aim of the present study was to assess the 
efficacy and toxicity of gemcitabine regimens in 
patients with relapsed or refractory lymphomas.
Material and Methods
The study included 68 patients (42 males and 
26 females) with HL and NHL. It was a multicenter 
study, enrolling patients at 5 institutions in Poland 
between May 2009 and January 2014. The partici-
pants included 42 patients with a histologic diag-
nosis of HL and 26 with NHL. The median age of 
the patients was 36 years (range: 21–71 years). Re-
lapsed or refractory disease was confirmed all the 
patients. In 18 patients (26%) a relapse of HL/NHL 
had occurred after autologous stem cell transplan-
tation (ASCT); 20  patients (29%) with HL/NHL 
had an early relapse of disease (less than 12 months 
after the last treatment). All the patients had previ-
ously been treated with at least two chemotherapy 
regimens and presented resistance or relapse after 
second-line chemotherapy (the median count of 
previous regimens was 4). The response after gem-
citabine therapy was assessed every three or six cy-
cles using the International Workshop Response 
Criteria for NHL [13]. All patients were evaluated 
by physical examination, computed tomography 
(CT) or positron emission tomography/computed 
tomography (PET/CT).
The overall response rate (ORR), overall surviv-
al (OS), progression-free survival (PFS) and toxici-
ty after gemcitabine treatment were analyzed. The 
ORR included complete response (CR) and partial 
response (PR). OS and PFS were determined using 
the Kaplan-Meier method. The log-rank test was 
used to compare the curves. A p value of < 0.05 was 
considered significant. All statistical analyses were 
performed using STATISTICA 8.0 software (Stat-
Soft, USA). The toxicity grade was evaluated ac-
cording to the National Cancer Institute Common 
Toxicity Criteria (NCI CTC) [14].
The clinical characteristics of the patients are 
summarized in Table 1.
Results
Treatment and Response
The study included 45 patients (66%) who were 
treated with gemcitabine in combination with oth-
er cytostatics. Gemcitabine-based chemotherapy 
included gemcitabine, vinorelbine and dexameth-
asone/prednisone (GVD/GVP) in 28  patients; 
gemcitabine, ifosfamide and vinorelbine (IGEV) 
in 16  patients; and gemcitabine, methylpredniso-
lone and cisplatin (GEM-P) in 1 patient. The other 
Table 1. Clinical characteristics of 68 patients
Gender 42 M/26 F





















Median of treatment 
regimens
4 (2–6)
HL – Hodgkin lymphoma, PTCL – peripheral T cell 
lymphoma, DLBCL – diffuse large B-cell lymphoma, 
MCL – mantle cell lymphoma, FL – follicular lymphoma.
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23 patients (34%) received gemcitabine monother-
apy. Gemcitabine monotherapy was used in elder-
ly patients and in patients with relapsed/refractory 
after high-dose therapy with ASCT (HDT-ASCT) 
who were not eligible for further intensive chemo-
therapy. The median count of gemcitabine based 
cycles was 4 (range: 3–12).
The ORR in the whole group of patients was 
46% (31 patients); it was higher in patients with HL 
than in patients with NHL (31% vs. 15%). CR was 
achieved in 14  patients (21%): in 5  patients with 
NHL and in 9 patients with HL. PR was achieved 
in 17 patients (25%): in six patients with NHL and 
in 11 patients with HL. Among the patients with 
PR, five were treated with gemcitabine monother-
apy. Among the patients with CR and PR, 26 (38%) 
were treated with high-dose therapy followed by 
autologous stem cell transplant (HDT-ASCT). 
Among them there were 17 patients with HL and 
nine patients with NHL. After HDT-ASCT 3 pa-
tients underwent allogeneic stem cell transplant.
The remaining patients comprised 32 (47%) 
who had progressive disease (PD) and 5 (7%) with 
stable disease (SD) after gemcitabine regimens.
Toxicity
In 23  patients treated with gemcitabine regi-
mens (34%), mild hematological toxicity (neu-
tropenia and thrombocytopenia grade 1/2) was 
observed. Grade 3/4 neutropenia occurred in 
12  patients (18%), thrombocytopenia in 11  pa-
tients (16%) and anemia in seven patients (10%). 
Ten patients with grade 3/4 neutropenia had neu-
tropenic fever. Three patients (4%) presented an 
allergic rash. One patient developed renal failure 
and in one patient ileus occurred. There were no 
treatment-related deaths.
Survival
The median PFS in all the patients was 
10  months (range: 2–52  months; Fig. 1). The 
median PFS in the patients who responded to 
gemcitabine therapy was 13  months (range: 
3–53 months; Fig. 2). The median OS after gem-
citabine therapy in all the patients was 17 months 
(range: 6–53  months; Fig. 3). The median OS in 
the patients who responded to gemcitabine ther-
apy was 21 months (range: 3–51 months; Fig. 4). 
The median OS in the patients treated with HDT- 
-ASCT after gemcitabine therapy was 26  months 
(range: 6–54 months).
PFS and OS after gemcitabine-based chemo-
therapy was longer in the patients with HL than in 
those with NHL (PFS 10 months vs. 6 months re-
spectively, and OS 15 months vs. 9 months). It was 
only a tendency; the difference was not statistical-
ly significant.
OS was significantly longer in the patients 
treated with gemcitabine in combination with 
other cytostatics than in those treated with gem-
citabine monotherapy (p = 0.01).
Discussion
The treatment of patients with relapsed or re-
fractory HL and NHL is challenging. High-dose 
chemotherapy followed by autologous stem cell 
transplant remains the standard approach for che-
mosensitive patients  [1]. However, there are no 
guidelines for patients with relapsed/refractory 
disease after second- or third-line treatment. There 
are limited options in this group of patients.
Barlett et al. reported 91 patients with relapsed 
HL treated with gemcitabine, vinorelbine and pe-
gylated iposomal doxorubicin. The ORR in that 
Fig. 1. The Kaplan-Meier estimate 
of PFS in all the patients
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Fig. 3. The Kaplan-Meier estimate of 
OS in all the patients
Fig. 4. The Kaplan-Meier estimate 
of OS in all the patients stratified by 
response to gemcitabine therapy. 
Group 1 – patients who had no 
response; Group 2 – patients who 
responded (CR and PR)
Fig. 2. The Kaplan-Meier estimate 
of PFS in all the patients stratified 
by response to gemcitabine therapy. 
Group 1 – patients who had no 
response; Group 2 – patients who 
responded (CR and PR)
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study group was 70%, with 19% CR. Toxicities in-
cluded mucositis in 23% of the patients and febrile 
neutropenia in 9%  [11]. Hawkes et  al. analyzed 
a population of 41 patients with relapsed/refracto-
ry HL who received the GEM-P regimen; the ORR 
to GEM-P was 80%, with 37% CR [15]. A study by 
Bai et  al. included patients with relapsed and re-
fractory aggressive NHL and HL. All the patients 
had been treated previously; the median count of 
courses of treatment was three. The patients re-
ceived the GVD regimen. The ORR in the whole 
group of patients was 48%, with 31% CR and 17% 
PR. The median PFS was 13  months for the pa-
tients who responded to GVD, and the median 
OS was 36 months. Among the patients with CR 
and PR, 16 were treated by HDT ASCT. In 34% 
of the patients neutropenia grade 3/4 occurred; in 
9% anemia occurred; and in 7% thrombocytope-
nia occurred [10].
The present study involved 68 heavily pre-
treated patients with relapsed or refractory HL 
and NHL. The median count of previous cours-
es of therapy in this group was four. All the pa-
tients were treated with gemcitabine monotherapy 
or gemcitabine in combination with other cyto-
statics. The ORR in this population was 46%; the 
ORR was higher (but not significantly) in the pa-
tients with HL in comparison with the patients 
with NHL (31% and 15%, respectively). These re-
sults are similar to the outcomes reported by Bai 
et al. with a similar population of patients [10].
In the present study the median PFS in pa-
tients who responded to gemcitabine treatment 
was 13 months, which was again comparable with 
the results of the study by Bai et al. [10]. In the pres-
ent study the median OS among the patients who 
responded to gemcitabine therapy was 21 months. 
This OS was shorter than in other reports, but in 
the group of patients who had HDT ASCT, the OS 
was longer: 26  months. A  tendency was also ob-
served that OS and PFS were longer in the patients 
with HL than in those with NHL.
Gemcitabine may be used both in patients el-
igible for more intensive treatment and in elderly 
or frail patients. The combination of gemcitabine 
with other cytostatics is a good therapeutic strat-
egy and results in a  reasonable response rate. In 
elderly patients or in patients with comorbidities, 
gemcitabine monotherapy allows the course of the 
disease to be controlled. In the present study 7% 
of the patients who had gemcitabine monotherapy 
achieved PR, while 7% of the whole study group 
achieved stable disease.
Relapsed/refractory NHL patients, especial-
ly those with aggressive lymphomas, have a poor-
er prognosis than HL patients. OS without stem 
cell transplantation in this population is less than 
1–2 years [16, 17]. In the present study, 24 patients 
(92%) with NHL had aggressive lymphomas, in-
cluding diffuse large B-cell lymphoma (DLBCL) 
in 15 cases. It seems that gemcitabine-based thera-
py could be a good option in patients with aggres-
sive lymphomas who have been heavily pretreat-
ed. A favorable option for patients with aggressive 
lymphomas is gemcitabine in combination with 
other chemotherapy agents  [18]. In a  phase I/II 
trial Evens et  al. analyzed the efficacy of gem-
citabine combined with bortezomib for relapsed/ 
/refractory DLBCL and peripheral T-cell lympho-
mas (PTCL). The study included 32 patients with 
DLBCL and PTCL, and the median number of pri-
or therapies was three. The ORR in this popula-
tion was 24%, with 19% CR. The ORR in DLBCL 
patients was 10% and in PTCL patients it was 
36% [19]. In a study by Mounier et al., 49 patients 
with refractory/relapsed DLBCL were treated with 
gemcitabine in combination with rituximab and 
oxaliplatin. After four cycles, 44% of the patients 
achieved CR and 17% achieved PR. The ORR for 
the whole group of patients was 61% [20]. Gem-
citabine in combination with immunotherapy or 
some immunomodulatory agents could be a  key 
to improving outcomes in aggressive relapsed/re-
fractory NHL.
The efficacy of gemcitabine therapy in patients 
with relapsed/refractory lymphomas is comparable 
with effect of lenalidomide or bendamustine. Iva-
nov et al. reported on 17 patients with relapsed/re-
fractory DLBCL who were treated with a combina-
tion of lenalidomide and rituximab. The ORR was 
41%, with 35% CR [21]. In another study lenalido-
mide was used as a single agent in relapsed/refrac-
tory mantle cell lymphoma (MCL) with an ORR of 
35% [22]. Patients with HL relapsed after autolo-
gous or autologous/allogeneic stem cell transplan-
tation were given salvage therapy with bendamus-
tine. The ORR in this population was 57%, with 
25% CR and 31% PR  [23]. Investigational thera-
pies including gemcitabine in combination with 
agents like lenalidomide or bendamustine could be 
a promising option for patients with poor-progno-
sis HL and NHL.
In retrospective study, Czyz et al. analyzed pa-
tients with relapsed HL after autologous stem cell 
transplant. There were 37  patients treated with 
gemcitabine-based regimens. The ORR in this 
population was 68%, with 22% CR and 46% PR. 
The patients with CR and PR had significantly 
longer OS and PFS; 15 patients who responded to 
gemcitabine therapy proceeded to allogeneic stem 
cell transplant and 5  patients to autologous stem 
cell transplant [24]. In another report, 40 patients 
with relapsed HL after HDT ASCT were treated 
with the GVD regimen and the ORR was 75% [11]. 
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In the present retrospective analysis, 26  patients 
who responded to gemcitabine treatment proceed-
ed to HDT-ASCT. In this group there were 12 pa-
tients (46%) who relapsed after HDT-ASCT. Mo-
bilization of CD34 (+) stem cells was effective in 
most of the patients. In three patients mobilization 
of stem cells after gemcitabine salvage therapy was 
unsuccessful (two patients with NHL and one pa-
tient with HL).
In the current study significant toxicity af-
ter gemcitabine treatment occurred in 30 patients 
(44%) and included grade 3/4 neutropenia, throm-
bocytopenia and anemia. Bai et al. described grade 
3/4 toxicities in 49% of the patients [10]. Czyz et al. 
reported neutropenia, thrombocytopenia and ane-
mia as the most common adverse events in patients 
treated with gemcitabine-based therapy [15].
The authors have concluded that salvage ther-
apy with gemcitabine is good as a bridging-cytore-
duction strategy to an autologous or allogeneic stem 
cell transplantation. Mobilization of stem cells after 
gemcitabine regimens is successful in most heavily 
pretreated patients. The results of this study suggest 
that gemcitabine-based chemotherapy is a  good 
treatment option for heavily pretreated patients 
with relapsed/refractory HL or NHL. Gemcitabine 
in combination or as monotherapy resulted in good 
disease control with an ORR of 46%, and it allows 
the mobilization and collection of CD34+ stem cells. 
Gemcitabine in combination with other cytostatics 
or new immunomodulatory agents is more effective 
than gemcitabine monotherapy, while gemcitabine 
as single agent could be a  solution for elderly pa-
tients or for patients with comorbidities.
The toxicity profile of gemcitabine regimens is 
acceptable with manageable hematological toxici-
ty. Therefore the results of this study should be val-
idated in prospective trials.
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